Cookies notice

This website uses cookies. By continuing to use this website, you consent to our use of these cookies. You can find out more about how we use cookies and how to manage them by reading our Cookie Policy.

Continue
ARIA

Allergic Rhinitis and its Impact on Asthma (ARIA)

The international ARIA guidelines on the pharmacological management of allergic rhinitis now include Dymista®.3

Ground breaking grading of recommendations3

The original 2010 ARIA guidelines were the first evidence-based recommendations in allergy to follow the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. In the GRADE system, recommendations are classed as “strong” or “conditional”, depending on the guideline panel’s confidence that following the recommendation would be more beneficial than harmful to patients.

The ARIA guideline panel included allergists, ear-nose-throat specialists, pulmonologists, general practitioners, and paediatricians.

The guidelines are aimed primarily at primary care clinicians, school nurses, pharmacists, specialists in allergy and clinical immunology, general internists managing patients with allergic rhinitis, and paediatricians.

Summary of recommendations for combination of an intranasal H1-antihistamine (INAH)3

In patients with seasonal allergic rhinitis (SAR), we suggest either a combination of an INCS with an INAH (Dymista®) or an INCS alone (conditional recommendation - moderate certainty of evidence).

In patients with perennial allergic rhinitis (PAR), we suggest either a combination of an INCS with an INAH (Dymista®) or an INCS alone (conditional recommendation - very low certainty of evidence).

In patients with SAR, we suggest a combination of an INCS with an INAH (Dymista®) rather than an INAH alone (conditional recommendation - low certainty of evidence).

INCS: intranasal corticosteroid; INAH: intranasal antihistamine

Dymista® is indicated for relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.4

Click here for the full ARIA guidelines

References

  • Scadding GK, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). Clin Exp Allergy 2017; 47(7): 856-889.
  • Scottish Medicine Consortium (SMC). Available at https://www.scottishmedicines.org.uk/medicines-advice/azelastine-hydrochloride-plus-fluticasone-propionate-dymista-abbreviatedsubmission-92113/. Last accessed: November 2018.
  • Brożek JL, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017; 140(4): 950-958.
  • Dymista®. Summary of product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9450/smpc.
    Last accessed: November 2018.

The website you are trying to access is designed for healthcare professionals in the UK, the content is not designed for the general public.

Are you a UK healthcare professional?

YES
NO

hcp popup title

Mylan Connects is an online platform for UK health Professionals.

Across the website you will find news, blogs and product information.

Register to Mylan Connects today

Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients.

REGISTER NOW

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Mylan by phone: 0800 121 8267 or by email: ukpharmacovigilance@mylan.com.

This website is owned and managed by Mylan. This site has been developed for use by healthcare professionals only. If you're a patient who has been prescribed Dymista® (azelastine hydrochloride/fluticasone propionate), please ​click here​

DYM-2020-0332 Date of preparation: May 2020.
Copyright © 2020 Mylan N.V. All rights reserved. Dymista® is a registered trademark of Mylan N.V.

Mylan UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781)

Mylan Logo